

Open Peer Review on Qeios

Ibrexafungerp

National Cancer Institute

Source

National Cancer Institute. <u>Ibrexafungerp</u>. NCI Thesaurus. Code C162185.

An intravenous and orally bioavailable semisynthetic derivative of enfumafungin with potential antifungal activity. Upon administration, ibrexafungerp inhibits beta-1,3-D-glucan synthase, an enzyme essential for fungal cell wall synthesis. This results in weakening of the fungal cell wall, thereby leading to osmotic lysis and eventually fungal cell death.

Qeios ID: E54HJ8 · https://doi.org/10.32388/E54HJ8